Esophageal cancer: The latest on chemoprevention and state of the art therapies.

Autor: Le Bras GF; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States., Farooq MH; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States., Falk GW; Division of Gastroenterology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States., Andl CD; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States. Electronic address: Claudia.andl@ucf.edu.
Jazyk: angličtina
Zdroj: Pharmacological research [Pharmacol Res] 2016 Nov; Vol. 113 (Pt A), pp. 236-244. Date of Electronic Publication: 2016 Aug 24.
DOI: 10.1016/j.phrs.2016.08.021
Abstrakt: Esophageal cancer is currently the 8th most common cancer worldwide and the 6th leading cause of cancer-related mortality. Despite remarkable advances, the mortality for those suffering from esophageal cancer remains high, with 5-year survival rates of less than 20%. In part, because most patients present with late-stage disease, long-term survival even after resection and therapy is disappointingly low. As we will discuss in this review, multiple characteristics specific to the disease stage and patient must be considered when choosing a treatment plan. This article will summarize current standard therapies, potential application of chemoprevention drugs and the promise and partial failure of personalized medicine, as well as novel treatments addressing this disease.
(Copyright © 2016 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: